OverviewSuggest Edit

Akoya Biosciences is a biotechnology company specializing in high-parameter tissue analysis. The company offers two platforms that allow investigators and researchers to gain a deeper understanding of cancer, autoimmune and neurological diseases. The CODEX system is a benchtop platform that can quantify more than 40 protein biomarkers and helps with biomarker discovery. The Phenoptics platform is an immunofluorescence solution for translational research and clinical trials.

TypePublic
Founded2015
HQMarlborough, MA, US
Websiteakoyabio.com
Employee Ratings4.2

Latest Updates

Employees (est.) (Dec 2020)169
Share Price (Sept 2021)$14(-7%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Akoya Biosciences

Niro Ramachandran

Niro Ramachandran

Chief Business Officer
Julia Kennedy

Julia Kennedy

Head of CODEX Research & Development
Cliff Hoyt

Cliff Hoyt

Vice President, Translational & Scientific Affairs
Frederic Pla

Frederic Pla

Chief Operating Officer
Gavin Gordon

Gavin Gordon

Vice President, Clinical Market Development
Nikolay Samusik

Nikolay Samusik

Co-Founder
Show more

Akoya Biosciences Office Locations

Akoya Biosciences has offices in Marlborough and Menlo Park
Marlborough, MA, US (HQ)
100 Campus Dr 6th floor, Marlborough
Menlo Park, CA, US
1080 O'Brien Dr Suite A
Menlo Park, CA, US
1505 O'Brien Dr suite a - 1
Show all (3)

Akoya Biosciences Financials and Metrics

Akoya Biosciences Revenue

USD

Revenue (Q2, 2021)

13.1m

Gross profit (Q2, 2021)

8.1m

Gross profit margin (Q2, 2021), %

62.2%

Net income (Q2, 2021)

(5.6m)

EBIT (Q2, 2021)

(6.4m)

Market capitalization (28-Sept-2021)

531.7m

Closing stock price (28-Sept-2021)

14.0

Cash (30-Jun-2021)

135.5m

EV

428.5m
Akoya Biosciences's current market capitalization is $531.7 m.
USDQ1, 2021Q2, 2021

Revenue

12.2m13.1m

Cost of goods sold

4.8m4.9m

Gross profit

7.4m8.1m

Gross profit Margin, %

61%62%
USDQ1, 2021Q2, 2021

Cash

11.7m135.5m

Accounts Receivable

6.6m8.2m

Inventories

4.7m6.6m

Current Assets

24.0m157.4m
USDQ1, 2021Q2, 2021

Net Income

(8.1m)(13.6m)

Depreciation and Amortization

1.0m2.2m

Inventories

(430.0k)(2.5m)

Accounts Payable

702.0k(176.0k)
USDQ1, 2021

Revenue/Employee

77.8k

Financial Leverage

-1.2 x
Show all financial metrics

Akoya Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Akoya Biosciences Online and Social Media Presence

Embed Graph

Akoya Biosciences News and Updates

Akoya Biosciences Appoints Diagnostics Industry Pioneer Myla Lai-Goldman, MD, to its Board of Directors

MARLBOROUGH, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the appointment of Myla Lai-Goldman, MD, a true pioneer and leader in the diagnostic industry, to its board of directors.

Akoya Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

MARLBOROUGH, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the Morgan Stanley 19th Annual Global Healthcare Conference.

Akoya Biosciences to Present at the Canaccord 41st Annual Growth Conference

MARLBOROUGH, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the Canaccord 41st Annual Growth Conference.

Akoya Biosciences Appoints Diagnostics Industry Leader Scott Mendel to its Board of Directors

MARLBOROUGH, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced the appointment of diagnostics industry leader Scott Mendel to its board of directors.

Akoya Biosciences Begins Accepting Applications for First-of-its-Kind Imaging Innovators (I²) Network

Seeking researchers interested in pushing the boundaries of spatial biology and discovery through the CODEX® system’s open, accessible interface Seeking researchers interested in pushing the boundaries of spatial biology and discovery through the CODEX® system’s open, accessible interface

Akoya Biosciences Announces Pricing of Initial Public Offering

MARLBOROUGH, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its initial public offering of 6,580,000 shares of its common stock at a price of $20.00 per share, for gross proceeds of $131.6 mil…

Akoya Biosciences Frequently Asked Questions

  • When was Akoya Biosciences founded?

    Akoya Biosciences was founded in 2015.

  • Who are Akoya Biosciences key executives?

    Akoya Biosciences's key executives are Niro Ramachandran, Julia Kennedy and Cliff Hoyt.

  • How many employees does Akoya Biosciences have?

    Akoya Biosciences has 169 employees.

  • Who are Akoya Biosciences competitors?

    Competitors of Akoya Biosciences include Inivata, ClearLight Biotechnologies and BioDataAnalysis.

  • Where is Akoya Biosciences headquarters?

    Akoya Biosciences headquarters is located at 100 Campus Dr 6th floor, Marlborough, Marlborough.

  • Where are Akoya Biosciences offices?

    Akoya Biosciences has offices in Marlborough and Menlo Park.

  • How many offices does Akoya Biosciences have?

    Akoya Biosciences has 3 offices.